These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36197130)

  • 1. An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer's Disease.
    Daly T; Herrup K; Espay AJ
    AJOB Neurosci; 2024; 15(2):80-81. PubMed ID: 36197130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current study on diagnosis and treatment of Alzheimer's disease by targeting amyloid b-protein.
    Hua KY; Zhao WJ
    Folia Neuropathol; 2023; 61(1):8-15. PubMed ID: 37114956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease.
    Ceyzériat K; Zilli T; Millet P; Frisoni GB; Garibotto V; Tournier BB
    Curr Alzheimer Res; 2020; 17(2):112-125. PubMed ID: 32129164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current Clinical Trials in the Treatment of Alzheimer's Disease].
    Tamaoka A
    Brain Nerve; 2020 Jan; 72(1):23-34. PubMed ID: 31907330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.
    Bateman RJ; Cummings J; Schobel S; Salloway S; Vellas B; Boada M; Black SE; Blennow K; Fontoura P; Klein G; Assunção SS; Smith J; Doody RS
    Alzheimers Res Ther; 2022 Nov; 14(1):178. PubMed ID: 36447240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():376-401. PubMed ID: 30273552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins.
    Kulichikhin KY; Fedotov SA; Rubel MS; Zalutskaya NM; Zobnina AE; Malikova OA; Neznanov NG; Chernoff YO; Rubel AA
    Prion; 2021 Dec; 15(1):56-69. PubMed ID: 33910450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease: where next for anti-amyloid therapies?
    Hardy J; De Strooper B
    Brain; 2017 Apr; 140(4):853-855. PubMed ID: 28375461
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
    Gauthier S; Leuzy A; Racine E; Rosa-Neto P
    Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once upon a time, the Amyloid Cascade Hypothesis.
    Granzotto A; Sensi SL
    Ageing Res Rev; 2024 Jan; 93():102161. PubMed ID: 38065226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned.
    Modrego P; Lobo A
    Neurodegener Dis Manag; 2019 Jun; 9(3):119-121. PubMed ID: 31116074
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteinopenia hypothesis: Loss of Aβ
    Espay AJ; Herrup K; Kepp KP; Daly T
    Ageing Res Rev; 2023 Dec; 92():102112. PubMed ID: 38270185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's Disease "Non-amyloidogenic" p3 Peptide Revisited: A Case for Amyloid-α.
    Kuhn AJ; Abrams BS; Knowlton S; Raskatov JA
    ACS Chem Neurosci; 2020 Jun; 11(11):1539-1544. PubMed ID: 32412731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensory gamma entrainment: Impact on amyloid protein and therapeutic mechanism.
    Hu J; Zheng L; Guan Z; Zhong K; Huang F; Huang Q; Yang J; Li W; Li S
    Brain Res Bull; 2023 Oct; 202():110750. PubMed ID: 37625524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
    Fedele E
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies.
    Digma LA; Winer JR; Greicius MD
    J Alzheimers Dis; 2024; 97(2):567-572. PubMed ID: 38250779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?
    Teich AF; Arancio O
    Biochem J; 2012 Sep; 446(2):165-77. PubMed ID: 22891628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.